We have studied the oncolytic efficacy of two adenovirus vectors named KD3 and INGN 007, which differ from each other only in that whereas KD3 has two small deletions in its e1a gene that restrict its replication to rapidly cycling cells, INGN 007 has wild-type e1a gene. Both vectors overexpress the adenovirus death protein (ADP). Both KD3 and INGN 007 effectively suppressed the growth of subcutaneous human A549 and Hep3B tumors in nude mice upon intratumoral injection, and contained the growth of subcutaneous LNCaP tumors after intravenous injection, making some tumors shrink or disappear. However, in a more demanding model, intravenous injections of neither KD3 nor wild-type Ad5 were effective against subcutaneous A549 tumors, whereas INGN 007 increased the mean survival time by 35%. INGN 007 was also effective in suppressing tumor growth in a challenging A549 orthotopic lung cancer model. INGN 007 was superior to dl1520 (ONYX-015) in repressing subcutaneous A549 tumors. Our results suggest that vectors such as INGN 007 might provide better antitumor efficacy in the clinic as well.
Introduction
Replication-competent (oncolytic) adenovirus (Ad) vectors have been developed as a promising new tool in the fight against cancer. 1 The principal idea behind this approach is that the vector replicates in the cancer cell, lyses the infected cell at the culmination of infection and releases progeny virus. These newly made virions in turn infect neighboring cells in the tumor, and start a new lytic cycle. In theory, such vectors should spread through and eliminate a tumor. Most oncolytic Ads constructed so far are derivatives of human wild-type serotype 5 (Ad5), a virus that causes mild respiratory illness in infants and no disease in immunocompetent adults. Ad5 is one of the best-studied viruses, is genetically stable, does not integrate into the host genome and can be produced in large amounts.
Researchers have introduced various genetic modifications to restrict Ad vector virus replication to cancerous cells. These modifications exploit genetic differences between normal and cancerous cells, for example, place essential viral genes under the control of promoters that are active only in tumor cells, delete viral genes that regulate pro-apoptotic cellular functions known to be active only in normal cells, disable the vector's capacity to drive the infected cell into the S-phase of the cell cycle, and so on.
Oncolytic Ad vectors carrying such mutations (for example, ONYX-015 [dl1520], 2 Ad5-CD/Tkrep, 3 CG7060 4 and CG7870 5 ) have been tested in human clinical trials. 6 All four vectors caused little toxicity, even when administered intravenously (i.v.) at dose levels of 1 Â 10 13 virus particles. However, their efficacy as single agents was limited; they produced better results when used in combination with chemotherapy. 7 ONYX-015 was the most extensively studied vector among the four with numerous phase I and phase II clinical studies, but it did not proceed through phase III clinical trials in the United States. However, the development of a very similar vector (named H101) occurred in China, and H101 has been approved as an anticancer drug in that country. 8 It is clear from these clinical experiments and others performed in animal models that the high anticancer efficacy seen in tissue culture with oncolytic Ads does not readily manifest in vivo. We believe that part of the reason for this is that in many cases the genetic modifications introduced to restrict virus replication to cancer cells attenuate the vector. Ad proteins routinely perform multiple functions; thus, the deletion of a gene in order to abolish one function (for example, downregulation of apoptosis in the case of deletion of the gene for the E1B-55K protein in ONYX-015) will have consequences on other viral functions (for example, Ad late mRNA export from the nucleus). In the case of promotersubstituted vectors, the cellular promoters may not be as efficient as the viral promoters that they have replaced. In addition, it may be impractical to produce the veryhigh-titer virus stocks required for administering high doses, especially as some of these vectors are impaired for growth.
To circumvent the vector attenuation problem, we have developed INGN 007 (a.k.a. VRX-007), 9 a fully replication-competent Ad vector. INGN 007 is not impaired for replication and relies on the natural tropism of Ads for cancerous cells for tumor targeting. Ads utilize the DNA replication machinery of the infected cell for their replication, and for this and probably other reasons, cells with a deregulated cell cycle (such as cancer cells) are more permissive for Ad replication than quiescent cells (most cells in an adult human). [10] [11] [12] INGN 007 spreads from cell to cell faster than wild-type Ad5 due to the overexpression of the E3-11.6K adenovirus death protein (ADP). 9 Overexpression of ADP also increases the spread of Ad vectors in vivo. 13 As it has been shown that vector dissemination within the tumor is crucial for efficacy, 14 we believe that ADP overexpression further enhances the anticancer efficacy of INGN 007 and other anticancer Ad vectors. 9, 13, 15, 16 Recently, we have reported on the largescale biodistribution and safety studies conducted with INGN 007 in two rodent species, the permissive Syrian hamster and the poorly permissive mouse. 17, 18 From these studies, we established that the safety profile of INGN 007 is similar to that of Ad5 in hamsters and that of Ad5 and a replication-defective Ad vector in mice. All the three vectors/viruses were distributed to most organs after i.v. injection. Both INGN 007 and Ad5 replicated in the lungs, livers and possibly kidneys of hamsters but not mice. As expected, the primary target organ for toxicity was the liver in both species, as evidenced by transient elevation of serum transaminase levels and by histopathological changes in the liver. A no observable adverse effect level of 3 Â 10 10 virus particles per kg was established for INGN 007 in hamsters. Based on preclinical data with INGN 007, the Food and Drug Administration approved a phase I clinical trial to test the safety of the vector.
In this study, we present data showing that INGN 007 is efficacious in repressing the growth of various tumors in animal models. We propose that INGN 007 and vectors such as INGN 007 can be used safely and effectively to treat cancer patients using intratumoral injection.
Materials and methods

Cells and viruses
MeWo melanoma and SQ-20B and HLaC head-and-neck cancer cells were received from Introgen Therapeutics Inc. (Houston, TX). A549 lung cancer, Hep3B hepatocellular carcinoma and LNCaP prostate cancer cells were obtained from ATCC (Bethesda, MD). All these cells were cultured in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) containing 10% fetal bovine serum at 37 1C in a humidified incubator under 5% CO 2 pressure. Normal human mammary epithelial cells (HMECs) were purchased from Clonetics (San Diego, CA), and were cultured in mammary epithelial growth medium (Clonetics).
The construction of INGN 007 9 and KD3 15 was described earlier. Briefly, KD3 is a deletion mutant of Ad5; it carries two small deletions in the e1a gene that preclude the binding of E1A protein to the Rb-family proteins and p300/CBP. Further, KD3 has all genes in the E3 region deleted, except for the 12.5K and adp genes. With KD3, the adp gene is reinserted such that the ADP protein is vastly overexpressed compared with wild-type Ad5. INGN 007 is identical to KD3, except that it has the wild-type e1a gene. The Ad5 mutant dl1520, 19 which is the same virus as ONYX-015, was obtained from Dr Arnie Berk (University of California at Los Angeles). dl1520 has the gene for E1B-55K deleted. It also has the genes for the E3 RIDa, RIDb and 14.7K proteins deleted, and has a small deletion in the gene for the E3-6.7K protein.
The vectors were propagated on suspension KB cells, purified by isopycnic equilibrium centrifugation and plaque titered on A549 cells. 20 Cell viability assay For the lactate dehydrogenase (LDH) release assay for cell lysis, MeWo, SQ-20B, HLaC and HMEC cells grown in 35 mm tissue culture dishes were infected at 1 plaqueforming unit (PFU) per cell in 1 ml of serum-free Dulbecco's modified Eagle's medium. After an adsorption period of 1 h, 1 ml of complete medium was added (final fetal bovine serum concentration of 5%). HMEC cells were infected in mammary epithelial growth medium or mammary epithelial basal medium. To make HMEC cells quiescent, they were grown to about 50% confluency in mammary epithelial growth medium, and then the medium was changed to human mammary epithelia basal medium without growth factors. With this method, the cell-doubling rate was decreased by 40%. Infected cells were incubated at 37 1C with 5% CO 2 . At 8 (MeWo, SQ-20B and HLaC) or 7 (HMEC) days post-infection (p.i.), supernatants were collected and microcentrifuged to remove floating cells. Total lysis samples were prepared by the addition of lysis buffer included in the Cyto Tox 96 kit (Promega, Madison, WI). Samples of volume 20 ml were assayed in triplicate using the LDH assay kit Cyto Tox 96 and read on an EL340 microplate reader (BioTec Instruments Inc., Winooski, VT) at 490 nm.
Animal experiments
Five-to six-week-old female athymic nude mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN). All experiments were carried out according to the animal protocol approved by the Animal Care and Use Committee of Saint Louis University. Tumor measurements were carried out with Sylvac (Crissier, Switzerland) digital calipers linked to the in-house developed Mouser Tumor Measurement and Analysis software. Tumor volumes were calculated according to the formula length Â width Â width/2. Subcutaneous tumors were generated by injecting 1 Â 10 7 A549, Hep3B or LNCaP cells in serum-free Dulbecco's modified Eagle's medium containing 10-50% Matrigel (BD Biosciences, San Jose, CA). When the tumors reached about 100 ml (300 ml for Hep3B) in size, the animals were injected either intratumorally or i.v. (into the tail vein) with 100 ml of vehicle (phosphatebuffered saline with 1 mM MgCl 2 and 1 mM CaCl 2 ) or vehicle containing virus vectors. For most experiments (except the LNCaP i.v. experiment with KD3), the doses were fractionated and given on three consecutive days.
The orthotopic lung tumor model was described earlier. 21 Briefly, mice were injected with 2 Â 10 6 A549 cells i.v. (tail vein). At 10 days post-injection, the animals were injected i.v. (jugular vein) with vehicle or vehicle containing various doses of INGN 007 for three consecutive days. At 21 days after the injection of cells, the animals were killed and the tumor nodules in the lungs were visualized using India ink.
The experiment to test the antiviral effect of CMX001 (hexadecyoxypropyl-cidofovir) against INGN 007 was performed in Syrian hamsters purchased from Harlan Sprague-Dawley as described previously.
22 CMX001 was obtained from Chimerix Inc. (Durham, NC). The animals were immunosuppressed with twice-weekly intraperitoneal injections of 100 mg per kg of cyclophosphamide following a single dose of 140 mg per kg of the drug, and injected i.v. with 3 Â 10 10 PFU of INGN 007, which is the lethal dose 50% of the virus in immunosuppressed hamsters. One group of animals was left untreated, and the other was treated with six daily doses of 2.5 mg per kg of CMX001 through oral gavage, starting a day before the injection of the vector. The animals were observed daily, and were killed when they became moribund.
Determining the infectious vector load of tumors
The infectious vector content of tumors was determined as described previously. 23 Briefly, at the completion of the experiment, the tumors were excised, weighed and homogenized. The homogenized extract was titered in a 50% tissue culture infective dose assay.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software package. Levene's test was used to test for homogeneity of data, analysis of variance to assay for overall effect and Student's t-test for pairwise comparisons. Kaplan-Meier analysis and log-rank statistics were utilized to assess statistical significance in survival assays. In all analyses, Pp0.05 was considered statistically significant.
Results
INGN 007 lyses cancer cells more effectively than wild-type Ad5
The overexpression of ADP is expected to raise the potency of INGN 007 to destroy cancer cells as compared with Ads expressing normal levels of ADP or no ADP at all. This has been established earlier with lung and liver cancer cell lines; 9 to expand these studies, we determined the ability (Table 1) . Nearly all cell lines examined were efficiently lysed by INGN 007, indicating that INGN 007 has a broad host range of cancer cells. However, as the structural proteins of INGN 007 are all derived from Ad5, the vector cannot infect CAR-negative cells efficiently in tissue culture (at 1 PFU per cell), as illustrated by its inability to lyse SKOV3 ovarian cancer cells.
INGN 007 replicates preferentially in cancer cells
Ads need a conducive cellular environment for successful replication, that is, an abundance of enzymes and precursor substances for macromolecular synthesis, and a relative lack of antiviral defense mechanisms. These conditions are readily found in cancer cells but not in most normal cells in an adult human. We have shown previously that INGN 007 replicates 100-fold better in A549 human lung cancer cells than in primary normal human bronchial epithelial cells. 21 The normal cells in that experiment were actively dividing; this is not the case with most terminally differentiated normal cells, which form the bulk of cells in the adult human body. To test whether quiescent conditions further decrease the ability of INGN 007 to kill normal cells, we compared the cytopathic effect induced by the vector upon infection of growing and growth-arrested HMECs by measuring LDH release. At 7 days p.i., 65% of the quiescent INGN 007-infected HMEC cells were still viable, as opposed to only 8% of the rapidly dividing HMEC cells (Figure 1c ).
CMX001 rescues immunosuppressed Syrian hamsters from a lethal challenge with INGN 007
We have demonstrated previously that the safety profile of INGN 007 is similar to that of wild-type Ad5.
17 Ad5 infections are usually asymptomatic in healthy adults, but the virus can cause severe disseminated infection in immunosuppressed patients. To emulate this situation, we have developed an animal model based on the Syrian hamster, which is permissive for species C human Ads. [24] [25] [26] [27] Immunosuppressed hamsters can be used to test the efficacy of antiviral drugs. 22 We tested the ability of an antiviral drug named CMX001 to prevent virus replication-associated toxicity in a hypothetical worst-case scenario, in which an extreme dose of INGN 007 has been introduced into the blood stream. CMX001 is a Fully replication-competent oncolytic adenovirus vector K Toth et al chain-terminator-type nucleoside analog that is linked to a lipid moiety for better bioavailability; it inhibits the replication of Ads. 22, 28 Immunosuppressed hamsters were injected i.v. with 3 Â 10 10 PFU of INGN 007. One group of animals was treated with daily doses of 2.5 mg per kg of CMX001 for seven consecutive days starting a day before vector injection, and the other group was left untreated. All of the eight treated hamsters completely recovered by the conclusion of the experiment, whereas three of the seven untreated animals died by 6 days post-injection ( Figure 2 ).
Intratumoral injection of INGN 007 and KD3 suppresses the growth of subcutaneous lung and liver cancer xenografts in nude mice We have reported earlier that the ADP-overexpressing oncolytic Ad vector named KD3 showed enhanced antitumor effect as compared with an Ad5 mutant (dl1101/1107), which has the same two e1a deletions as does KD3 but does not overexpress ADP. 15 The replication of KD3 is restricted to cells with a deregulated cell cycle owing to the two short deletions in the e1a gene; in every other respect it is identical to INGN 007. The anticancer efficacy of INGN 007 upon intratumoral The rate of cell lysis was determined by various methods; in some experiments membrane integrity was measured, in others indirect immunofluorescence and yet in others the vector spread assay was used. +++, very rapid lysis; ++, rapid lysis; +, lysis; À, no lysis. (Figure 4 ).
Both KD3 and INGN 007 are efficacious against LNCaP tumors following intravenous injection of the vectors
The purpose of these experiments was not to compare KD3 with INGN 007, but rather to determine how well these vectors could repress subcutaneous LNCaP tumors following i.v. administration. LNCaP tumors are frequently studied by Ad vector research groups. [29] [30] [31] LNCaP tumors were induced similarly to the A549 tumors described above. When the tumors grew to about 100 ml in size, the mice were injected i. INGN 007 suppresses the growth of subcutaneous human lung tumors in nude mice to a greater extent than dl1520 We compared the efficacy of INGN 007 with that of the well-studied vector dl1520 (ONYX-015). Subcutaneous A549 human lung tumors were injected intratumorally with vehicle or 9 Â 10 8 PFU of INGN 007 or dl1520, fractionated into three daily doses. Up to about 10 days p.i., the two suppressed tumor growth to a similar extent. However, in the second half of the experiment, the tumor suppression by INGN 007 was significantly better than that by dl1520 (Figure 7a) .
We determined the amount of infectious vector in the tumors at the completion of the experiment (25 days after the injection of vectors). Consistent with the efficacy data, there was approximately 500-fold more live vector in the 
Discussion
In the past few years, several oncolytic Ad vectors have been characterized in clinical trials. Although most of these trials were aimed at establishing the safety of the vectors (none of the replication-competent Ad vectors tested so far caused any dose-limiting toxicity), the limited amount of data that was collected indicated that, with few exceptions, their antitumor efficacy was less than that might have been desired. All the oncolytic Ad vectors showed limited efficacy as single agents, which was augmented in some cases by the concomitant use of radiation or chemotherapy. 7 All these vectors carried one or more mutations that restricted the replication of the virus to cancerous cells. In our judgment, the attenuation resulting from these genetic changes is one of the causes for the limited antitumor efficacy exhibited in the human clinical trials. As an alternative to the so far tested replication-competent Ad vectors, we have developed INGN 007, a fully replication-competent oncolytic Ad vector. We have shown previously that INGN 007 has a faster replication cycle and is more cytolytic in vitro than wild-type Ad5 owing to overexpression of ADP. 9 Another drawback of oncolytic Ad vectors with restricted replication is that often they are effective against only a specific type of cancer, or a subset of cancers, as was the case with KD3 (data not shown). INGN 007 has a broad spectrum; it very effectively lysed a panel of various types of cancer cells, irrespective of their genetic background.
This difference in host range manifests in vivo as well. Both vectors proved very effective in certain tumor models, such as intratumoral injection into subcutaneous A549 or LNCaP tumors. In accord with in vitro data (not shown), there was a marginal difference in efficacy, favoring INGN 007, in Hep3B cells. That KD3 performed as well or nearly as well as INGN 007 in subcutaneous tumors upon intratumoral injection is not surprising, as KD3 is a very potent vector itself. 15 However, the advantage of INGN 007 over KD3 became obvious when the vectors were tested head-to-head in a more rigorous model, in which the vectors were administered systemically to treat subcutaneous A549 tumors. In this system, only a fraction of the injected vector dose reaches the target tumors, and those few infecting virus particles have to replicate sufficiently to have an effect on tumor growth. In this system, INGN 007 fared much better than KD3-or Ad5-treated animals ( Figure 5 ). That INGN 007 was more effective in this model than Ad5 is particularly interesting, and might reflect the effect of ADP overexpression.
In an orthotopic disseminated lung tumor model, INGN 007 was effective against more established nodules but not against nodules consisting of a few cells only, inasmuch as it did not reduce the prevalence of tumors when it was applied 3 days after the cells were injected (data not shown). This suggests that an intravascularly administered oncolytic Ad might preferentially act on larger tumors, possibly because the vector gains access to those tumors through the blood supply, and that small, not yet vascularized tumors might escape infection.
INGN 007 replicated better in vivo in subcutaneous lung tumors than did dl1520, the same virus as ONYX-015, a vector that has been extensively tested both in pre-clinical and clinical studies (reviewed in Alemany 33 and Kumar et al.
34
). This better replication resulted in significantly more efficacious tumor suppression. We predict that just as in animals, INGN 007 would perform better than ONYX-015 in cancer patients. The photographs for each group were scanned and then analyzed with Adobe Photoshop software. The mean luminosity of all the pixels in the same area of each lung was measured and averaged for each group (n ¼ 6/group). *Po0.05; **Po0.001 (Student's t-test).
Fully replication-competent oncolytic adenovirus vector K Toth et al Although INGN 007 does not have an engineered genetic feature to restrict its replication to cancerous cells, it nevertheless replicates much more poorly in normal cells than in cancer cells, 21 and its replication is even less efficient in quiescent primary cells. This difference probably reflects the inherent preferential replication of human species C Ads in cancerous cells. 11, 12 As the vast majority of normal cells in patients are differentiated, quiescent cells, INGN 007 would probably replicate poorly in those. There are certain types of cells, for example, hematopoietic cells and stem cells, that proliferate rapidly. However, species C Ads do not infect these cells well because these cells lack CAR (the Ad5 receptor) and seem to have other features that restrict Ad replication.
About 40-60% of the population has circulating antibodies against Ad5. Although this might hinder systemic administration of Ad5-based vectors, neutralizing antibodies can provide an extra layer of safety to oncolytic Ads. We reported that pre-existing immunity does not significantly alter the oncolytic efficacy of INGN 007, 24 but it does alleviate the toxicity of INGN 007 25 in the permissive, immunocompetent Syrian hamster model. These data indicate that a vector entering the circulation would be quickly inactivated by neutralizing antibodies in patients with previous exposure to Ad5.
Previously, we have shown that the antiviral drug CMX001 could protect immunosuppressed hamsters from lethal challenge by Ad5. 22 As expected, CMX001 was fully effective in stopping INGN 007 replication and limiting toxicity in the same animal model. As this model represents a truly worst-case scenario, that is, i.v. injection of an extreme dose of an oncolytic Ad vector into a drastically immunosuppressed patient, we believe that this drug could be used to prevent viral toxicity in the unlikely event of runaway vector replication.
Based on these results, we suggest that a fully replication-competent oncolytic Ad vector such as INGN 007 could be developed as an anticancer agent. The vector will rely on the natural preference of species C Ads for replication in cancerous cells and in permissive proliferating cells. The potentially stronger side effects would be balanced by higher efficacy at lower doses; thus, such a vector would provide a therapeutic window comparable to or even wider than a tumor-restricted one. Furthermore, unlike many tumor-restricted Ad vectors, Ads with wild-type replication capabilities are easy to produce in high titers needed for clinical applications. Such vectors could be injected intratumorally; this approach limits the dissemination of the virus mostly to the injected locale. 26 As Ad5, the parental virus for most replication-competent Ad vectors, does not cause clinically significant illness in immunocompetent adults and is quickly eliminated by the immune system, we expect that a fully replicationcompetent Ad vector might have similar characteristics in patients. This claim is supported by the fact that INGN 007 has a similar safety profile as Ad5 in hamsters. 17, 18 Moreover, with INGN 007, the deletion of the immunomodulatory E3 genes 35 is expected to further increase safety by exposing the vector-infected cells to the host immune system. Further, there is at least one antiviral drug available that is able to mitigate the toxic effects of resulting from the replication of an oncolytic Ad.
Based on these results, we believe that INGN 007 warrants development as a novel anticancer agent.
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